The frequency of cardiac implantable electronic devices (CIED) is constantly increasing. Devices infections are one of the most serious complications in terms of morbidity and mortality. Although the frequency of cardiac implantable devices infections is difficult to derminate due to divergent definitions, cohort studies report a trend of increasing. The infection can be localized at the pocket of the implantation, at intravascular or intra-cardiac portion of leads. Infectious endocarditis defined by involvement of the intra-cardiac portion of leads is the most serious form. The diagnosis is based on clinical, biological and multimodal imagery data. Early diagnosis and specific management are necessary to reduce mortality and morbidity. Since the last European recommendations on infectious endocarditis in 2015, the HeartRythm Society of patient described an algorithm to treat CIED infections and extraction indications. However, in practice, management of CEID infections remains center-dependent and data from robust international studies are missing. The main objective of our study is to evaluate the management of CEID suspected infections and the prognosis at 1 year in terms of survival according to the methods of treatment at the Nancy University Hospital and to compare the treatment with the latest recommendations in force
Study Type
OBSERVATIONAL
Enrollment
184
No intervention, description of the diagnostic evaluation and the treatment
De Ciancio
Vandœuvre-lès-Nancy, France
Description of the practice
Describe the diagnostic and therapeutic practices of patients hospitalized for CIED suspected infection
Time frame: From January 2014 to July 2020
Evaluation of local practices against current recommendations
* Classify patients in 3 groups (1 = Cardiac implantable electronic device infection ; 2 Pocket infection without proof of lead involvements ; 3 = systemic infection related to infective valvular endocarditis or not without proof of lead involvements according to our local practices and criteria, to EHRA criteria and modified Duke Li criteria). * Compare diagnostic management in our center with EHRA recommendations in each groups * Compare therapeutic management including removal/extraction of cardiac implantable electronic device, antibiotic therapy * Assessment of adhering to EHRA recommendations * Pronostic evaluation according to removal/extraction or not based on survival curve
Time frame: From January 2014 to July 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.